Alloplex Biotherapeutics

Executive Summary

Alloplex Biotherapeutics is a private Phase 2 biotechnology company based in Boston, founded in 2016. The company has developed a patented cell-retraining platform that leverages synergistic interactions between key immune pathways, uncovering a previously unappreciated dimension of human immunology. This platform has the potential to address a wide range of cancers and immune-mediated diseases by reprogramming the patient's own immune cells to mount a more effective and durable response. Alloplex is currently advancing its lead program through Phase 2 clinical development, with a focus on demonstrating proof-of-concept in solid tumors. The company's innovative approach, combined with its strong scientific foundation, positions it as a promising player in the cell therapy landscape. While financial details and specific pipeline data are not publicly available, the platform's broad applicability and early clinical progress suggest significant upside potential.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Clinical Data Readout for Lead Program55% success
• Q2 2027Strategic Partnership or Licensing Deal40% success
• Q3 2027IND Filing for Second Indication60% success